SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $152.1 million in its second quarter.

On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of $2.13.

The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.67 per share.

The biopharmaceutical company posted revenue of $165.5 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $145.8 million.

PTC Therapeutics expects full-year revenue in the range of $700 million to $750 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PTCT at https://www.zacks.com/ap/PTCT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News